



























Cardiovascular disease is the leading cause of death in 
the United States, accounting for nearly one third of all 
mortalities [9]. While lifestyle modifications, drug 
development, and surgical technologies have increased 
the average life expectancy of humans, the risk and 
rates of heart disease continue to grow as the population 
ages. The process of aging causes unique physiological, 
histological, and biochemical changes in cardiac tissue. 
For example, aging cardiac myocytes are incapable of 
proliferation and cannot be reprogrammed transcrip-
tionally in response to changes in workload [7]. Age-
associated conditions such as buildup of reactive 
oxygen species, mechanical dysfunction, or other forms 
of trauma, have been linked to the development of 
hypertrophy and other cardiac pathologies [6, 14]. 
Therefore, development of drugs that target age-
dependent signaling pathways may provide promising 
therapeutic strategies for the treatment of heart disease.  
 
mIGF-1 protects the heart through crosstalk with 
SIRT1 
 
A study by Vinciguerra et al. published in the January 
2010 issue of Aging furnishes new and important 
information about the cellular mechanisms leading to 
the  pathogenesis  of heart  failure  [22].  They propose a  
 
 


























cardio-protective link between locally acting insulin-
like growth factor (mIGF-1) and the NAD+-dependent 
deacetylase SIRT1. Typically, it is thought that the 
highly conserved IGF-1 and sirtuin signaling pathways 
play antagonizing roles in mammalian physiology. IGF-
1 acts primarily as a growth hormone and signaling 
factor. Mice lacking GH/IGF-I signaling and IGF-1 
receptor heterozygous knockout mice have longer 
lifespans, and overexpression of a hormone known to 
inhibit insulin/IGF-1 signaling extends lifespan [5, 18]. 
However, the complex structure of the Igf-1 gene gives 
rise to multiple peptide isoforms that have contrasting 
functions [21]. Notably, the mIGF-1 isoform, which is 
expressed at high levels in neonatal tissues and adult 
liver, promotes regenerative properties in damaged 
heart tissue [21].  
 
SIRT1, the mammalian orthologue of yeast Sir2, is a 
highly conserved NAD+-dependant protein deacetylases 
that has emerged as an important regulator of aging and 
metabolic disease [2]. SIRT1 and its family members 
are reported to promote longevity in different model 
organisms, including yeast, worm and fly [2, 13]. The 
mammalian SIRT1 protein is primarily nuclear, and its 
functions have been tied to metabolism, cell survival 
and stress response [4]. The full-body SIRT1 knockout 
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[10], but a severe developmental phenotype, together 
with high neonatal mortality rates make use of it 
difficult to study the physiological role of SIRT1 in the 
adult heart. Interestingly, high levels of SIRT1 
expression (>9-fold) in the heart causes hypertrophy, 
loss of cardiac function, and elevated apoptosis [1]. On 
the other hand, moderate overexpression (2.5 to 7-fold) 
of SIRT1 in transgenic mouse hearts protects against 
oxidative stress, and results in increased expression of 
antioxidants [1]. As well, SIRT1 expression is increased 
in the hypertrophic heart of rodents and monkeys, 
though its functional relevance remains unclear [19].  
 
Vinciguerra et al. hypothesize that although SIRT1 and 








































isoform displays a novel cross-talk signaling program 
with SIRT1, which results in cardiomyocite protection 
from hypertrophic and oxidative stress. They show that 
mIGF-1-mediated activation of SIRT1 induces 
expression of the protective signaling molecules UCP1, 
adiponectin, and MT2 [22]. They suggest that SIRT1 
activation in the heart may also elicit protection from 
hypertrophy by restoring expression of fetal α-myosin 
heavy chain 7. The authors note an important distinction 
between circulating IGF-1 and mIGF-1. Typically, 
circulating IGF-1 activates PI3K/AKT/mTor and MAP 
kinase pathways, whereas mIGF-1 signals through 
PDK1 and SGK1 [22]. They conclude that the divergent 
signaling mechanisms between the two IGF-1 isoforms 
may account for their opposing effects in heart tissue 












































Sirtuin  Location  Activity  Transgenic Mouse Phenotype 
SIRT1 Nucleus  NAD-dependent  deacetylase 
KO – Ventricular abnormalities 
Tg – Overexpression (>9-fold) – Cardiac hypertrophy 
Tg – Overexpression (2.5 to 7-fold) – Protection from oxidative stress 
                                                          – Increased expression of antioxidants 
SIRT 3  Mitochondria/nucleus NAD-dependent  deacetylase 
KO – Cardiac hypertrophy 
Tg – Overexpression – Cardio-protective 
SIRT 7  Not established  NAD-dependent deacetylase/ 
ribosomal biogenesis  KO – Cardiac hypertrophy 
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Recently, two additional sirtuin family members—
SIRT3 and SIRT7--have been shown to have beneficial 
functions in the heart (Table 1), [17, 20]. SIRT3, which 
consists of two isoforms (≈28 kDa and ≈44 kDa) was 
initially identified as a mitochondrial protein, but has 
since been identified in the nucleus as well [15, 16]. 
Similar to SIRT1, SIRT3 uses NAD+ as a cofactor for 
the deacetylation of target substrates [2, 12]. Cellular 
energy status, reflected in NAD+ levels and 
NAD+/NADH ratios, are thought to influence SIRT1 
and SIRT3 expression and activity [8]. For example, 
mild stress conditions, such as mechanical stress to the 
heart and calorie restriction (CR), are presumed to 
reduce NADH levels, thus increasing the NAD+/NADH 
ratio. These alterations in cellular energy provide fuel to 
drive induction of SIRT3 during physiologic and mild 
hypertrophy.  
 
SIRT3-deficient mice show signs of cardiac 
hypertrophy and interstitial fibrosis at 8 weeks of age, 
while SIRT3 transgenic overexpressing mice are 
protected from application of hypertrophic stimuli [17]. 
SIRT3 blocks the cardiac hypertrophic response through 
activation of Foxo-dependent antioxidants, manganese 
superoxide dismutase (MnSOD) and catalase, as well as 
suppressing ROS-mediated Ras activation and the 
downstream MAPK/ERK and PI3K/Akt signaling 
pathways [17]. SIRT1 and SIRT3 appear to share 
similar ROS-accumulating end-point targets that cause 
cardiac hypertrophy. Use and development of sirtuin-
specific activators and inhibitors may help further 
dissect the collaborative functions of SIRT1 and SIRT3 
in the heart. 
 
Less is known about the physiological role of SIRT7 in 
the heart. SIRT7 is a nuclear protein that associates with 
rDNA and interacts with RNA [3]. It is not certain 
whether SIRT7 exhibits NAD+-dependent deacetylase 
activity, but reports suggest that it does respond to 
metabolic conditions by stimulating ribosomal 
biogenesis in dividing cells [11]. SIRT7-deficient mice 
develop heart hypertrophy and inflammatory cardio-
myopathy, which is characterized by extensive fibrosis 
[20]. SIRT7 appears to regulate heart cell death and 
damage by inhibiting p53, Ras, and Akt signaling 
pathways [20]. The molecular details explaining how 




Sirtuins are longevity factors that also appear to regulate 
critical cardio-protective pathways in the mammalian 
heart. To date, three family members—SIRT1, SIRT3, 
and SIRT7—have been shown to block stress-induced 
cardiac hypertrophy by impinging upon ROS 
generation. It is interesting that knockout mice for each 
sirtuin isotype exhibit heart abnormalities, while 
transgenic overexpression of all three provides protec-
tion from cardiac hypertrophy. More investigation using 
conditional knockout models and specific activators is 
needed to elucidate the distinct molecular functions of 
each sirtuin. These studies will have profound 
implications, not only for the management of heart 
failure, but also for other stress-associated diseases.   
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